Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D052160:Benzothiazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D001688:Biological Products / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D034261:Epothilones / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D014404:Tubulin / Q000378:metabolism
D000970:Antineoplastic Agents; D052160:Benzothiazoles; D001688:Biological Products; D034261:Epothilones; D014404:Tubulin; C530494:sagopilone